We are intellectual property litigators and counselors. Our focus affords you sound expertise and strategic guidance. And while our firm practices solely in the intellectual property arena, we have subspecialties in that space, with teams focusing on life sciences, biomedical, telecommunications, and software industries.
Our substantive knowledge of pharmaceutical and nutraceutical arts, combined with decades of experience litigating patent disputes, yields unparalleled advocacy in life sciences intellectual property cases.

Carlson Caspers’ life sciences team has extensive experience with intellectual property needs of pharmaceutical and nutraceutical companies, including our longstanding representation of the world’s largest generic drug manufacturer. We represent drug companies challenging patents covering the world’s top-selling pharmaceutical products, such as OxyContin®, Protonix®, Lunesta®, Zantac®, and Prilosec®. We also vigorously enforce the patent rights of our generic drug and nutraceutical clients—both big and small.

In support of our life sciences focus, we have built a team with scientific backgrounds tailored to address the technical issues posed by pharmaceutical and nutraceutical cases. Our members have undergraduate and graduate degrees in cellular biology, biochemistry, pharmacy, genetics, chemical engineering, and physics. We remain connected to these industries—regularly attending pharmaceutical and nutraceutical events. But our attorneys are not just scientists; they are experts in intellectual property law. Many of our attorneys have clerked in federal courts, several with the Federal Circuit—the federal appellate court for all patent appeals.

We concentrate on the trial and appeal of patent cases, but we also have extensive experience navigating clients through complex business issues outside litigation. We help clients create business plans to develop, enforce, and monetize patent portfolios; negotiate licenses; conduct pre-suit investigations; perform due diligence investigations in support of product launches, mergers, acquisitions, and divestitures; and represent clients in contested United States Patent and Trademark Office proceedings.

Few firms bring the combination of legal expertise, industry knowledge, and real-world business perspective that Carlson Caspers offers its clients. Even fewer offer these assets with the cost-effectiveness and billing flexibility of our firm. Whether representing a small start-up company or a large multinational conglomerate, we staff and manage each case in light of our clients’ business objectives and budgets. We also appreciate the importance of managing financial expectations, so we offer flexible arrangements, such as fixed fee and structured monthly fee agreements, to avoid budgeting surprises.

Consider Carlson Caspers—our life sciences patent litigation team is second to none.
Valensa and University of Illinois v. Cyanotech and Nutrex-Hawaii

Carlson Caspers represented Valensa, an innovator in the extraction, stabilization, and delivery of botanical extracts, and the University of Illinois in a lawsuit brought against Cyanotech and Nutrex-Hawaii for infringement of a patent covering the use of astaxanthin. This dispute involved litigation in both the district court and the United States Patent and Trademark Office. In the patent office, we successfully avoided institution of an IPR on a number of challenged claims and prevailed on a number of claims on which trial was instituted. Following expert discovery in the district court, the case was settled without trial.

Purdue v. Teva Pharmaceuticals USA, Inc. (oxycodone)

Carlson Caspers won a series of significant victories for Teva Pharmaceuticals USA, Inc., involving patents related to Purdue’s multi-billion dollar OxyContin® pain medication. First, Carlson Caspers secured favorable judgments on each of the asserted patents in a bench trial before US District Judge Sidney Stein of the Southern District of New York. Of the five patents in dispute, Judge Sidney Stein agreed with Teva’s “clear and convincing evidence” that four of Purdue’s patents lacked “novelty” and/or were “obvious.” The judge further ruled that Teva had not infringed the fifth patent and that the patent was invalid for indefiniteness. Purdue appealed four of these judgments to the Federal Circuit, and Carlson Caspers successfully defeated these appellate challenges, paving the way for Teva’s marketing of a generic OxyContin® product. Carlson Caspers also represented Teva in a second bench trial involving two additional tamper resistance patents listed in the Orange Book for OxyContin®. Shortly before the parties began a third trial, and before the Court issued a verdict on the second trial, Teva secured a favorable settlement.

UCB, Inc. v. Alembic Pharmaceuticals Ltd. (lacosamide)

Carlson Caspers represents Alembic in a case involving Alembic’s efforts to market a generic version of the antiepileptic drug lacosamide (UCB’s Vimpat®) by challenging the asserted compound patent. The case is pending.

Par Pharmaceutical, Inc. v. Breckenridge Pharmaceutical, Inc. (megestrol acetate)

Carlson Caspers represents Breckenridge in support of its efforts to market a generic version of megestrol acetate oral suspension (Megace® ES) by challenging two asserted formulation patents. The case is pending.
OSI Pharmaceuticals, Inc., Pfizer, Inc. and Genentech, Inc. v. Teva Pharmaceuticals USA, Inc., et al. (erlotinib)

Carlson Caspers represented Teva, one of two first-filers, against charges of infringement of compound, polymorph, and method patents relating to erlotinib (Tarceva®) in this Paragraph IV Hatch-Waxman case. Sales of Tarceva®, indicated for non-small-cell lung cancer and pancreatic cancer, were in excess of $1 billion annually. After taking the case from another firm, we built such a convincing case of noninfringement and invalidity that our client was offered a favorable settlement the first day of trial, whereas the other defendant was left to try the case alone.

Abbott Laboratories, Inc. v. Teva Pharmaceuticals USA, Inc., et al. (niacin and simvastatin)

Carlson Caspers represented the first-to-file generic drug company in a Paragraph IV Hatch-Waxman case involving eight Abbott patents directed to pharmaceutical products containing niacin and simvastatin (Simcor®) and methods of using those products. Despite the complexity and nuance of the subject matter resulting from the number of patents, technologies, and defenses at issue, our client received a favorable settlement offer and secured an early entry date for its product.

Altana Pharma AG and Wyeth v. Teva Pharmaceuticals USA, Inc. (pantoprazole)

Carlson Caspers’ client, Teva, was the first drug manufacturer to file a Paragraph IV ANDA challenging the validity of a patent covering pantoprazole (Protonix®), a product with annual US sales in excess of $2 billion. The patent at issue was a compound patent, covering the active pharmaceutical ingredient itself, widely regarded by branded pharmaceutical companies as the most important and difficult to invalidate patents. Discovery was long and difficult, and as the 30-month stay precluding FDA approval of Teva’s ANDA neared expiration, the patentee filed a motion for a preliminary injunction seeking to enjoin Teva from selling its proposed product. Our team defeated the motion, marking the first time a court denied a motion for a preliminary injunction in a case involving a pharmaceutical compound patent. We successfully defended the decision at the Federal Circuit. As a result, our client could begin to sell its product on the market years before expiration of the compound patent for pantoprazole.

Hoffmann-La Roche v. Teva Pharmaceuticals USA, Inc. (capecitabine)

Carlson Caspers represented Teva in this Paragraph IV Hatch-Waxman case concerning Teva’s ANDA for capecitabine (Xeloda®), which challenged the infringement and validity of the listed Orange Book patents. This case settled on favorable terms on the eve of trial.

Takeda Pharmaceutical Company, et al. v. Watson Pharmaceuticals, Inc., et al. (ramelteon)

Carlson Caspers represented Watson, first-to-file, in a Paragraph IV Hatch-Waxman case against charges of infringement of a patent directed to the active ingredient ramelteon, contained in Takeda’s Rozerem® sleep aid. The case settled on terms favorable to our client.

Kemin Foods v. OmniActive Health Technologies (lutein)

Carlson Caspers defended OmniActive, accused of infringing a patent on a pure form of lutein, a widely marketed nutraceutical agent. The case settled on favorable terms for our client.

Sabinsa v. Leward Resources and Indfrag (coleus forskohlin)

Carlson Caspers successfully represented Leward Resources and Indfrag, an Indian nutraceutical company, in an infringement action involving a patent covering coleus forskohlin for weight loss. The case settled favorably for our clients, permitting them to launch their product in the United States.

Sunovion v. Teva Pharmaceuticals USA, Inc. (eszopiclone)

Carlson Caspers represented Teva, a first-filer, in a Paragraph IV Hatch-Waxman case concerning Teva’s ANDA challenging the patents covering eszopiclone, the active ingredient of Lunesta®. Teva obtained a favorable settlement and resolved the matter short of trial.
Key Pharmaceuticals v. Schwarz Pharma (nitroglycerin transdermal patch)
Our attorneys represented Schwarz Pharma in this Paragraph IV Hatch-Waxman case over their efforts to introduce a generic version of a transdermal nitroglycerin patch to treat angina. Following a successful Markman determination, Schwarz Pharma secured a settlement agreement permitting it to bring its generic patch to market.

Celgene v. Teva Pharmaceuticals USA, Inc. (dexamethasone)
Carlson Caspers represented Teva in this Paragraph IV Hatch-Waxman case (and several related cases) over its efforts to introduce a generic version of Focalin® (dexamethasone) into the consumer market. We achieved a successful settlement for our client.

Astra v. Kremers Urban Development Co. and Schwarz Pharma (omeprazole)
Our attorneys represented Kremers and Schwarz Pharma in support of their ANDA seeking permission to launch omeprazole (Prilosec®) into the consumer market. Enjoying sales estimated $10 million per day, Astra mounted an extraordinary effort to enforce their patents. The case against Kremers and Schwarz was placed into multidistrict litigation with three other defendants. Our attorneys represented the clients at trial, after which only Kremers and Schwarz were found not to infringe the patents, permitting them to introduce a generic version of Prilosec®.

Glaxo v. Teva Pharmaceuticals USA, Inc. (ranitidine)
Our attorneys represented Teva in this Paragraph IV Hatch-Waxman case over its efforts to introduce a generic version of ranitidine (Zantac®) oral solution despite Glaxo’s charges of patent infringement. After we filed a motion for summary judgment, the case settled favorably for Teva.

AstraZeneca v. Teva Pharmaceuticals USA, Inc. and Glenmark Generics, Inc. USA (saxagliptin)
Carlson Caspers represented Teva and Glenmark in this Paragraph IV Hatch-Waxman case concerning the drug saxagliptin (Onglyza®), which challenged the infringement of a listed Orange Book patent. We successfully negotiated with AstraZeneca for early dismissal of both Teva and Glenmark based on their non-infringement of the asserted patent.

Takeda Pharmaceutical Company v. Watson Pharmaceuticals, Inc. (colchicine)
We represented Watson in this Hatch-Waxman patent litigation involving Watson’s ANDA for a generic version of Takeda’s Colcrys® colchicine tablets. Takeda asserted 17 patents covering several uses of colchicine. The case is currently stayed pending FTC approval of settlement.

Sanofi-Aventis v. Glenmark Generics, Inc. USA (dronedarone)
Carlson Caspers represented Glenmark in this Hatch-Waxman patent litigation concerning Glenmark’s Paragraph IV ANDA challenge of 3 patents covering the formulation and uses of dronedarone (Multaq®). We achieved a successful settlement for our client on the eve of trial.

Millennium Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., et al. (bortezomib)
Carlson Caspers represents Teva in this Hatch-Waxman patent litigation in support of its efforts to make a generic version of bortezomib (Vercade®) for the treatment of patients with multiple myeloma. The case is currently pending.

Forest Labs, et al. v. Teva Pharmaceuticals USA, Inc., et al. (memantine extended-release)
Carlson Caspers represented Teva in this Hatch-Waxman patent litigation concerning seven patents directed to formulations and uses of memantine extended-release (Namenda® XR). After all of the other generic drug company defendants settled, our attorneys represented Teva on the sole remaining defendant at trial. We achieved a successful settlement for our client after trial.
Carlson Caspers represents Sun Pharma Global FZE and Sun Pharmaceutical Industries, Ltd. (jointly, “Sun”) in a patent lawsuit filed by Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals America, Inc. based on Sun’s ANDA submission, which seeks FDA approval to manufacture and sell lansoprazole orally disintegrating tablets (Prevacid® SoluTab™). The case is venued in the district of New Jersey and is currently pending.

Sanofi-Aventis US LLC, et al. v. Glenmark Generics Inc., USA, et al. (cabazitaxel)
Carlson Caspers represents Glenmark in this patent litigation concerning the drug cabazitaxel injection (Jevtana®), which challenges the validity/infringement of a patent directed to methods of treatment. The case is currently pending.

Laboratoire HRA Pharma v. Teva Pharmaceuticals USA, Inc. (ulipristal)
We represented Teva, the first-to-file, in a Paragraph IV Hatch-Waxman action which challenges the infringement and/or validity of five patents covering the formulation and method of using the drug ulipristal (ella®). The case settled on favorable terms.

Boehringer Ingelheim Pharma GmbH & Co. KG, et al. v. Teva Pharmaceuticals USA, Inc. and Breckenridge Pharmaceuticals, Inc. (dabigatran):
Carlson Caspers represents Teva and Breckenridge in this Hatch-Waxman patent litigation concerning the drug dabigatran etexilate (Pradaxa®), which challenges the validity/infringement of a patent directed to compounds and methods of treatment. The case is currently pending.

Representative post grant matters

Pack Pharmaceuticals, LLC v. Alza Corp. (glipizide)
An attorney at Carlson Caspers (while at a previous law firm) represented Pack in an Inter Partes Review concerning Pack’s Paragraph IV ANDA challenge of 1 patent covering the formulation of glipizide (Glucotrol® XL). He achieved a successful settlement prior to the institution of the IPR.

Teva Pharmaceuticals USA, Inc. v. Eli Lilly and Company (pemetrexed sodium)
Carlson Caspers represents Teva in three Inter Partes Reviews (IPRs) concerning Teva’s Paragraph IV ANDA challenge of 1 patent covering methods of using the active pharmaceutical ingredient (API) present in the drug pemetrexed sodium (Alimta®). The three IPRs were filed during the related Hatch-Waxman patent litigation and are currently pending.

Alembic Pharmaceuticals, Ltd. v. Research Corporation Technologies (lacosamide)
Carlson Caspers represents Alembic in an Inter Partes Review (IPR) concerning Alembic’s Paragraph IV ANDA challenge of 1 patent covering the active pharmaceutical ingredient (API) present in the drug lacosamide (Vimpat®), compositions containing the API, and methods of using the API. The IPR was filed during the related Hatch-Waxman patent litigation and is currently pending.

Teva Pharmaceuticals USA, Inc. v. AstraZeneca (saxagliptin hydrochloride)
Carlson Caspers represents Teva in an Inter Partes Review (IPR) concerning Teva’s Paragraph IV ANDA challenge of 1 patent covering the active pharmaceutical ingredient (API) present in the drug saxagliptin hydrochloride (Onglyza®), compositions containing the API, and methods of using the API. The IPR was filed during the related Hatch-Waxman patent litigation and is currently pending.
Opinions, Pre-suit Investigations, and Transactional Representation

In addition to litigation under the Hatch-Waxman Act, our pharmaceutical IP services include strategic counseling, pre-suit analysis, Paragraph IV letters, opinion letters, and settlement. We have provided these services to the world’s leading pharmaceutical companies for nearly two decades, and have drafted over 100 Paragraph IV letters and opinion letters. Our team includes several registered U.S. patent attorneys who have extensive experience practicing before the United States Patent and Trademark Office (USPTO) and who hold advanced degrees in the life sciences.

In addition to drafting and negotiating a wide variety of agreements for our clients, our transactional attorneys provide comprehensive advice and expertise in transactions related to Hatch-Waxman issues.

USPTO Trials and Post-Grant Proceedings

We are one of the few firms well-positioned to handle the unique and often complicated aspects of trials and post-grant proceedings before the USPTO. Our dedicated team of patent attorneys and paralegals have extensive experience that allow us to successfully manage and resolve Inter Partes Reviews (IPRs), Post Grant Reviews (PGRs), patent interferences, and derivation proceedings—from initial review by the USPTO Patent Trial and Appeal Board (PTAB) through final hearing by the US Court of Appeals for the Federal Circuit. Since the enactment of the America Invents Act (AIA) in September 2012, we have handled a dozen IPRs, making us one of the top ANDA Hatch-Waxman litigation firms actively engaged in this practice area. Indeed, our USPTO-registered attorneys are involved in all aspects of inter partes proceedings. We regularly develop strategies that help our clients both invoke and avoid those proceedings. Leveraging our vitally important litigation skills and deep technical expertise in the life sciences, we proactively establish strong positions that, in many cases, prevents long and costly opposition.

Our attorneys
Mark D. Schuman

mschuman@carlsoncaspers.com
612.436.9650

Mark is a named partner with the firm. Mark’s practice encompasses contested matters in the US District Courts, state courts, and administrative agencies. Mark has participated in many district court trials to both the bench and jury on matters related to patents, trademarks, and other intellectual property rights. He also has participated in many Markman hearings. Mark obtained a temporary restraining order and seizure order against a Taiwanese company. He also has headed ANDA litigation over the drugs OxyContin®, Prilosec®, Protonix®, Zantac® oral solution, Axert®, and Nitro-Dur®. Mark’s technology exposure has been broad. He has headed litigation involving electronic circuitry, mechanical devices, optics, surface roughness, chemical compositions, adhesives, software, and pharmaceutical drugs. Mark’s other work experiences include advising clients on licensing and providing infringement and validity opinions. He has advised clients on “designaround” strategies. Mark is active in bar organizations and is the past Chair of AIPLA’s Patent Litigation Committee. He also served on AIPLA’s nomination committee.

Education

University of Wisconsin, Madison
JD, cum laude
Order of the Coif
Editor, Law Review

Northwestern University
BS Chemical Engineering, with distinction
Tau Beta Pi
Omega Chi Epsilon

Bar Admissions

Minnesota Supreme Court
Wisconsin Supreme Court
US District Court for the District of Minnesota
US District Court for the Eastern District of Michigan
US District Court for the Eastern District of Wisconsin
US District Court for the Federal Circuit
US Court of Appeals for the Eighth Federal Circuit
US Court of Appeals for the Tenth Federal Circuit
US Patent and Trademark Office
US Supreme Court

Jeffer Ali

jali@carlsoncaspers.com
612.436.9657

Jeff is a litigator who advises and represents clients in intellectual property matters, with particular emphasis in the life sciences. Having obtained a Doctor of Pharmacy degree and practiced as a pharmacist before attending law school, Jeff has represented some of the world’s largest generic pharmaceutical companies in generic pharmaceutical ANDA patent litigation. Jeff has been lead counsel in ANDA actions involving Namenda XR®, Multaq®, Xeloda®, Focalin®, Tarceva®, Vimpat®, and Megace ES®. Recent trial experience includes favorable settlement during trial of Tarceva® and trials of Namenda XR® and reformulated OxyContin®. Jeff also manages pharmaceutical opinion work and notice letter/detailed statement preparation before litigation.

Jeff has represented clients in other technologies, including software, medical devices, and various mechanical arts. Besides litigating patent disputes, Jeff also litigates trademark, copyright, and trade secret matters. Jeff has been recognized as a “Super Lawyer” by Minnesota Law & Politics magazine for several years. Jeff has made it a regular part of his practice to volunteer his time for legal-related causes. He has performed hundreds of hours of pro bono work and served on the boards of directors for the Volunteer Lawyers Network and the Fund for the Legal Aid Society of Minneapolis. Jeff is a past recipient of the Private Practice Pro Bono Lawyer of the Year awarded by the Hennepin County Volunteer Lawyers Network. He has also taught as an adjunct professor for the University of Minnesota Law School’s Intellectual Property Moot Court.

Education

University of Michigan
PharmD

University of Minnesota Law School
JD, cum laude

Bar Admissions

Minnesota Supreme Court
US District Court for the District of Minnesota
US District Court for the Eastern District of Wisconsin
US Court of Appeals for the Federal Circuit
US Patent and Trademark Office
Iain A. McIntyre
imcintyre@carlsoncaspers.com
612.436.9610

Iain dedicates most of his time to high technology patent issues and performs a variety of counseling functions. He conducts pre-suit investigations and IP due diligence investigations and provides freedom-to-operate and opinions relating to infringement and validity. Iain also drafts and negotiates patent licenses and develops patent procurement and patent prosecution strategies. He has been involved in many post-grant procedures in front of the PTO. Iain has a strong technical background and significant expertise in Patent Office practice and procedure. For the past several years, Iain has devoted significant time to preparing opinions relating to and litigating pharmaceutical patents, and he is experienced in preparing and serving Hatch-Waxman “Paragraph IV” notice letters and detailed statements. He has represented several generic pharmaceutical companies in several ANDA patent litigations. His practice covers a variety of other technologies, including medical devices, antibacterial vaccines, polymer technologies, software, optical devices and systems, and semiconductor devices. In 2002, he was named by Minnesota Lawyer magazine as one of the Top 10 Up and Coming Attorneys in Minnesota.

Education
University of Minnesota
Master of Biological Sciences

William Mitchell College of Law
JD, summa cum laude

University of St. Andrews, Scotland
PhD Physics

University of Strathclyde, Scotland
BSc, Applied Physics, 1st class honors

Bar Admissions
Minnesota Supreme Court
US District Court for the
District of Minnesota
US Court of Appeals for the
Federal Circuit
US Patent and Trademark Office

Matthew J. Goggin
mgoggin@carlsoncaspers.com
612.436.9624

Matt is an intellectual property litigator with 25 years of experience in all aspects of litigation through trial. He is an aggressive advocate who has successfully represented clients in patent cases involving a broad spectrum of technologies – everything from pitchforks and flytraps to polymer gels, cardiovascular stents, and pharmaceuticals.

Education
University of Minnesota Law School
JD, magna cum laude
Order of the Coif
Phi Kappa Phi

Washington University in St. Louis
BA, Biology

Bar Admissions
Minnesota Supreme Court
US District Court for the
District of Minnesota
US Court of Appeals for the Federal Circuit
US Patent and Trademark Office
Gary J. Speier

gspeier@carlsoncaspers.com
612.436.9643

Gary has a focus on issues facing companies in the life sciences sectors. He provides counsel on patent-related matters—conducting pre-suit investigations, IP valuations, and due diligence. He provides freedom-to-operate clearance reviews and opinions relating to infringement and validity, and develops patent procurement and prosecution strategies for domestic, international, and foreign jurisdictions. Gary is also involved in many post-grant proceedings in front of the U.S. Patent and Trademark Office (USPTO). Gary has devoted significant time to preparing opinions relating to pharmaceutical patents, has prepared and served numerous Hatch Waxman “Paragraph IV” notice letters and statements, and represented generic pharmaceutical companies in ANDA patent litigations. For example, Todd recently represented Teva Pharmaceuticals in a series of bench trials challenging the validity of patents listed in the Orange Book for Purdue’s multibillion-dollar OxyContin® product. Todd and his colleagues secured invalidity verdicts at each of these trials, and successfully defended those victories on appeal to the Federal Circuit.

Todd Werner
twerner@carlsoncaspers.com
612.436.9655

For over a decade, Todd has focused his practice on Hatch-Waxman patent litigation, nutraceutical litigation, contested patent office proceedings (IPRs), and counseling. Leveraging his degree in biochemistry, Todd has extensive experience representing generic pharmaceutical companies challenging the patent rights of their competitors through ANDA litigation. For example, Todd recently represented Teva Pharmaceuticals in a series of bench trials challenging the validity of patents listed in the Orange Book for Purdue’s multibillion-dollar OxyContin® product. Todd and his colleagues secured invalidity verdicts at each of these trials, and successfully defended those victories on appeal to the Federal Circuit.

Todd has also successfully represented patentees. For example, Valensa and the University of Illinois retained Todd to enforce a patent directed to the use of astaxanthin—a naturally occurring carotenoid—to improve eye health. Todd secured a favorable settlement after successfully defending a number of claims challenged at the patent office in an IPR proceeding.

Todd has litigated patent infringement disputes in various other disciplines as well, including the electrical, chemical, and mechanical arts. He has handled a number of IPRs, both offensive and defensive, and provides counsel in the negotiation of intellectual property licenses and joint development agreements. Todd has been named a “Super Lawyer” in patent litigation each year from 2013 until present, and was previously selected as a “Rising Star” each year from 2008–2012. Todd has also taught Intellectual Property Moot Court at the University of Minnesota Law School, and represented indigent clients in employment litigation at the federal court through the Federal Bar Association’s Pro Se Project. He was also identified by the Minnesota State Bar Association as a North Star lawyer in 2014 for his pro bono service.

Education

Temple University School of Law
JD

University of Massachusetts, Amherst
MBA, Finance, Beta Gamma Sigma

Villanova University
MSc Synthetic Organic Chemistry

Fordham University
BSc Chemistry, Sigma Xi

Bar Admissions

Minnesota Supreme Court
North Dakota Supreme Court
Supreme Court of New Jersey
Supreme Court of Pennsylvania
U.S. District Court for the District of New Jersey
U.S. Patent and Trademark Office

Bar Admissions

University of Minnesota Law School
JD, cum laude

Michigan Technological University
BS, Biochemistry, summa cum laude

Bar Admissions

Minnesota Supreme Court
US District Court for the District of Minnesota
US Court of Appeals for the Federal Circuit
Samuel T. Lockner
slockner@carlsoncaspers.com
612.436.9654

Sam concentrates his practice on intellectual property litigation and licensing. He focuses on patent disputes filed under the Hatch-Waxman Act (“ANDA litigation”). He was recently trial counsel for Teva Pharmaceuticals USA, Inc. in a patent dispute involving the blockbuster drug, tamper-resistant OxyContin®. The Carlson Caspers trial team won the case, as the Court held the two asserted patents invalid and ruled that Teva did not infringe one. Other ANDA litigation experience includes cases involving molecules, formulations, and methods-of-use patents covering proton-pump inhibitors, phenidate drugs, combination therapies, sleep aids, and oncology drugs. Sam represented several biomedical device companies in patent disputes as both plaintiffs and as defendants and handled many contested copyright and trademark matters in federal court and before administrative tribunals (for example, the Trademark Trial and Appeal Board). Sam has represented clients large and small in licensing deals, and he has extensive experience with agreements involving intellectual property, including research collaboration agreements, technology transfer agreements, material transfer agreements, and confidentiality agreements. Sam recently closed a licensing deal valued at more than $25 million. He is active in the legal community and performs substantial pro bono work. Sam has been consistently named a “Rising Star” by Minnesota Law & Politics and Minnesota Super Lawyers magazines from 2008 to 2014.

Sarah M. Stensland
sstensland@carlsoncaspers.com
612.436.9651

Sarah practices intellectual property law with a focus on patent litigation. She was recently part of the trial team for Teva Pharmaceuticals in an ANDA action involving tamper resistant OxyContin® in which the patents were invalidated. Sarah has also represented generic pharmaceutical companies in ANDA actions involving Multaq®, Vimpat®, Ella®, and Xeloda®. As a lawyer and chemical engineer, Sarah represents clients in patent infringement actions, with an emphasis on defending generic pharmaceutical companies in Hatch-Waxman litigation.

In the April 2014 issue of Mpls.St.Paul Magazine and the April 2013 issue of Twin Cities Business, Sarah was listed among the “Top Women Attorneys in Minnesota.” Since 2012, Sarah has been named a “Rising Star” by Super Lawyers. Sarah is a member of the Leadership Committee of Minnesota Women Lawyers. Sarah is also a volunteer attorney with the Children’s Law Center. In law school, Sarah was a staff member of the William Mitchell Law Review.

Education
University of Iowa
BS, Chemical Engineering
William Mitchell College of Law
JD, magna cum laude
William Mitchell Law Review, Vol. 31, Staff Member

Bar Admissions
Minnesota Supreme Court
US District Court for the District of Minnesota
US Court of Appeals for the Federal Circuit

Sarah practices intellectual property law with a focus on patent litigation. She was recently part of the trial team for Teva Pharmaceuticals in an ANDA action involving tamper resistant OxyContin® in which the patents were invalidated. Sarah has also represented generic pharmaceutical companies in ANDA actions involving Multaq®, Vimpat®, Ella®, and Xeloda®. As a lawyer and chemical engineer, Sarah represents clients in patent infringement actions, with an emphasis on defending generic pharmaceutical companies in Hatch-Waxman litigation.

In the April 2014 issue of Mpls.St.Paul Magazine and the April 2013 issue of Twin Cities Business, Sarah was listed among the “Top Women Attorneys in Minnesota.” Since 2012, Sarah has been named a “Rising Star” by Super Lawyers. Sarah is a member of the Leadership Committee of Minnesota Women Lawyers. Sarah is also a volunteer attorney with the Children’s Law Center. In law school, Sarah was a staff member of the William Mitchell Law Review.

Education
University of Minnesota
BS, Genetics Cell Biology and Development
Boston University School of Law
JD, cum laude
Health Law Concentration with honors
Dean’s Award for Trademark and Unfair Competition

Bar Admissions
Minnesota Supreme Court
US District Court for the District of Minnesota
US Court of Appeals for the Federal Circuit

Education
University of Iowa
BS, Chemical Engineering
William Mitchell College of Law
JD, magna cum laude
William Mitchell Law Review, Vol. 31, Staff Member

Bar Admissions
Minnesota Supreme Court
US District Court for the District of Minnesota
US Court of Appeals for the Federal Circuit
Alex practices intellectual property law with an emphasis on patent litigation. During law school, Alex clerked as a judicial extern for the Honorable Randy J. Holland of the Delaware Supreme Court. She also conducted research in patent and trademark law for Professor Mark Janis and held leadership roles in the Organization for Women Law Students and Staff, Phi Delta Phi, and the Intellectual Property Law Society. Prior to law school, Alex earned her degree in chemical engineering with a focus on biochemical engineering. As an undergraduate, she conducted research in nanotechnology, particularly focusing on photopolymerization kinetics.

### Education
- University of Iowa College of Engineering
  - BS, Chemical Engineering, with honors, with highest distinction
- University of Iowa College of Law
  - JD, with highest distinction
  - Order of the Coif
  - Articles Editor, Journal of Corporation Law

### Bar Admissions
- Minnesota Supreme Court
- US District Court for the District of Minnesota

---

Jennell practices intellectual property law with an emphasis on patent, trade secret, and trademark disputes. She represents clients on both litigation and related counseling and opinion work. Among recent matters, Jennell was part of the core team that helped Teva Pharmaceuticals invalidate several patents listed in the Orange Book for OxyContin®, from initial discovery through two bench trials. She has also counseled clients through settlement negotiations relating to IP disputes before litigation ensues. As a pharmacist and, prior to joining Carlson Caspers, co-founder of a pharmacy benefits and formulary consulting company, Jennell blends her scientific, business, and legal knowledge to help clients reach favorable outcomes. Prior to joining Carlson Caspers, Jennell also assisted with expert consulting in litigation involving antitrust, pharmaceutical pricing and promotion, misappropriation of trade secrets and unfair competition, and ANDA matters.

Jennell is an adjunct assistant professor in the College of Pharmacy at the University of Minnesota where she is the course director for Pharmacy Law. She is a council member to the Minnesota State Bar Association’s Food, Drug and Device Law Section, and has represented clients in employment litigation through the Minnesota Federal Bar Association’s Pro Se project. Since 2013, Super Lawyers has named her a “Rising Star.”

### Education
- William Mitchell College of Law
  - JD, cum laude
- Co-Editor-in-Chief, Cybaris® an Intellectual Property Law Review
- Assistant Editor, William Mitchell Law Review
- CALI Awards, Antitrust and IP Appellate Practice
- University of Minnesota, College of Pharmacy
  - PhD, Social & Administrative Pharmacy
- University of Minnesota, College of Pharmacy
  - PharmD
- Iowa State University
  - BS, Journalism, with distinction
  - Phi Beta Kappa

### Bar Admissions
- Minnesota Supreme Court
- US District Court for the District of Minnesota
- US Court of Appeals for the Federal Circuit
Caroline L. Marsili
cmarsili@carlsoncaspers.com
612.436.9652

Caroline practices intellectual property law with an emphasis on patent litigation. She also has experience in antitrust litigation and clearance investigations. She has worked on matters involving a range of technologies, including pharmaceuticals, medical devices, and lawn care equipment, and is a regular contributor to the ANDA Advisors Blog. During law school, Caroline gained experience in both patent and trademark prosecution, was Editor-in-Chief of the Minnesota Journal of Law, Science & Technology, and graduated with a concentration in intellectual property and technology law. Caroline served as a judicial extern for the Honorable Francis J. Connolly of the Minnesota Court of Appeals. Prior to law school, Caroline earned her degree in biology with an emphasis on genetics and developmental neurobiology. She also conducted research in the area of pathology, particularly focusing on familial breast cancer.

Publication


Education

University of Minnesota Law School
JD, magna cum laude
Editor-in-Chief, Minnesota Journal of Law, Science & Technology
Carleton College
BA, Biology, cum laude

Bar Admissions

Minnesota Supreme Court
US District Court for the
District of Minnesota

Nathan D. Louwagie
nlouwagie@carlsoncaspers.com
612.436.9656

Nate practices intellectual property law with an emphasis on patent litigation and counseling. He represents U.S. and foreign clients from a broad range of industries, including pharmaceuticals, medical devices and chemicals. Nate is a member of teams providing counsel on ANDA disputes, international and cross-border patent disputes and other matters.

Nate is a registered patent agent with the U.S. Patent and Trademark Office. He served as a legal extern for the Hon. Patrick J. Schiltz of the U.S. District Court for the District of Minnesota. He also is a member of the Communications Committee of the Minnesota Chapter of the Federal Bar Association.

After earning his undergraduate degree in chemistry, Nate served for one year as a paid research intern in Medtronic Inc.’s highly competitive Technical Internship Program. At Medtronic, he worked on a team in collaboration with an outside technology partner to achieve demonstrably higher volumetric energy density in implanted medical batteries. During college, Nate was involved in research projects both at St. John’s University and at Southwest University in Chongqing China. He is the co-author of an article published in the Journal of Chemical Research related to this research.

Nate has represented clients in pro bono matters involving landlord-tenant issues, in conjunction with the Volunteer Lawyers Network, as well as in disputes involving enforcement of municipal building codes. After finishing his internship at Medtronic, he served as volunteer in the IFRE program in Nepal. Nate played rugby at St. John’s University and was a member of the Eastside Banshees Rugby Club for several years.

Education

University of Minnesota Law School
JD, Cum Laude
Concentration in Intellectual Property and Technology
Kenneth R. & Lillian Smith Scholarship
Dean’s List
St. John’s University, BA
Phi Beta Kappa
Distinction in Chemistry
Dean’s List

Bar Admissions

Minnesota Supreme Court
U.S. District Court for the
District of Minnesota
Shelleaha L. Jonas

sjonas@carlsoncaspers.com
612.436.9607

A licensed pharmacist, Shelly advises health care, medical device and pharmaceutical clients on a broad range of legal matters, including the interpretation and application of federal and state statutes, regulations and administrative agency guidance. Among recent matters, she helped a Fortune 500 managed health care company review and interpret contracts with private, state and federal entities, and conducted business-unit research to help develop effective litigation strategies.

In addition to her private-sector health care experience, Shelly has extensive firsthand knowledge of governmental policies, processes and regulatory compliance issues. She completed an externship at the U.S. Food and Drug Administration offices in Maryland, where she focused on laws and regulations governing drugs, biologics and medical devices. In addition, during her externship at the Minnesota Department of Human Services, she reviewed Medicaid programs to ensure compliance with state and federal law, and drafted documents to educate prescribers about new patient-safety initiatives.

While in law school, Shelly served as articles submission editor of the Minnesota Law Review and as a student instructor of legal writing and research. Shelly is an Adjunct Assistant Professor at the University of Minnesota College of Pharmacy, where she serves as Course Director of Pharmacy Law.

---

Education

University of Minnesota Law School
J.D., magna cum laude
Order of the Coif

University of Minnesota College of Pharmacy
Pharm.D., summa cum laude
Rho Chi Honor Society

University of Minnesota
B.A., Biology, Society, and Environment

Bar Admissions

Minnesota Supreme Court
U.S. District Court for the District of Minnesota